Nothing said here yet.
to join the conversation.
Edgewise Therapeutics (EWTX) has attracted considerable investor interest in the upcoming phase 3 de
Edgewise Therapeutics has dosed the first patient in EQUINOX-HFpEF, a Phase 2, randomized, double-blind, placebo-controlled trial of its oral cardiac sarcomere modulator EDG-15400 in adults aged 30 to 84 with symptomatic HFpEF and left ventricular ejection…
– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 – BOULDER, Colo., Oct.
Edgewise Therapeutics (EWTX) drew fresh attention after scheduling a special call on September 22, 2026, to walk through the differentiated mechanism of action for its cardiac sarcomere modulator EDG-7500.
Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:30 a.m.
UTHR, NMRA, and EWTX are drawing attention from options bears
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights.
How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past day but higher over the past month and past 3 months.